Spruce Biosciences Inc (SPRB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$46.61+8.88%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SPRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -68.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
SPRB — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this
Why it matters: Spruce is losing money and has no approved product in these inputs. Cash updates show whether it can fund plans through key TA-ERT steps.
Worry ifA company filing or earnings update says cash can fund planned operations and debt beyond the second half of 2027. It discloses no new financing.
Less concerning ifSpruce says its cash will not cover planned operations into the second half of 2027. It announces a new stock sale or loan to extend its runway.
Why it matters: The program could give treatment access to children who cannot join the main study. Its launch also tests Spruce's plans to expand access.
Supportive ifSpruce reports that the expanded access program has started by December 31, 2026, with enrollment open at U.S. sites.
Worry ifThe program has not started by year-end, or Spruce reports that it is delayed or canceled.
Why it matters: The FDA asked Spruce to start this study while the BLA is under review. It is a key step tied to possible accelerated approval.
Supportive ifSpruce reports that the TrAnsform study has started by December 31, 2026.
Worry ifThe study has not started by year-end, or Spruce reports a delay to its start.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$254 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $923 loss on $10,000 · 9.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,931 loss on $10,000 · 69.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.